Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Telitacicept in Healthy Chinese Adults
NCT04235933Phase 1Completed
- Sponsor
- RemeGen
- Start
- Sep 2019
- Primary completion
- Dec 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of telitacicept in systemic lupus erythematosus (SLE), sponsored by RemeGen. Primary endpoints: Maximum Plasma Concentration at Day 57, Time to Maximum Plasma Concentration at Day 57 and 3 more. Started Sep 2019; status: completed.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04235933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04235933.